JP2005522229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005522229A5 JP2005522229A5 JP2003584733A JP2003584733A JP2005522229A5 JP 2005522229 A5 JP2005522229 A5 JP 2005522229A5 JP 2003584733 A JP2003584733 A JP 2003584733A JP 2003584733 A JP2003584733 A JP 2003584733A JP 2005522229 A5 JP2005522229 A5 JP 2005522229A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- ccmp
- expression
- nucleic acid
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 239000000126 substance Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 239000003153 chemical reaction reagent Substances 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 238000012216 screening Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0208089.3A GB0208089D0 (en) | 2002-04-09 | 2002-04-09 | Protein |
| PCT/GB2003/001593 WO2003087841A2 (en) | 2002-04-09 | 2003-04-09 | An ephrin-b receptor protein involved in carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009284833A Division JP2010101901A (ja) | 2002-04-09 | 2009-12-16 | 癌に関与するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005522229A JP2005522229A (ja) | 2005-07-28 |
| JP2005522229A5 true JP2005522229A5 (enExample) | 2006-07-06 |
Family
ID=9934469
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003584733A Pending JP2005522229A (ja) | 2002-04-09 | 2003-04-09 | 癌に関与する蛋白質 |
| JP2009284833A Pending JP2010101901A (ja) | 2002-04-09 | 2009-12-16 | 癌に関与するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009284833A Pending JP2010101901A (ja) | 2002-04-09 | 2009-12-16 | 癌に関与するタンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7655426B2 (enExample) |
| EP (1) | EP1497659A2 (enExample) |
| JP (2) | JP2005522229A (enExample) |
| AU (1) | AU2003227862B2 (enExample) |
| CA (1) | CA2479835C (enExample) |
| GB (1) | GB0208089D0 (enExample) |
| WO (1) | WO2003087841A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006255536A1 (en) | 2005-06-03 | 2006-12-14 | Novartis Vaccines And Diagnostics Inc. | Methods of treating, diagnosing or detecting cancer using an EphB3 modulator |
| US8586716B2 (en) * | 2006-08-04 | 2013-11-19 | Novartis Ag | EPHB3-specific antibody and uses thereof |
| KR20140119831A (ko) * | 2006-12-07 | 2014-10-10 | 노파르티스 아게 | Ephb3에 대한 길항제 항체 |
| US20100041048A1 (en) * | 2008-07-31 | 2010-02-18 | The Johns Hopkins University | Circulating Mutant DNA to Assess Tumor Dynamics |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4233782A1 (de) | 1992-10-07 | 1994-04-14 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Klonierung eines neuen Mitgliedes der Familie der Rezeptor-Protein-Tyrosin-Kinasen |
| US5506205A (en) * | 1993-11-24 | 1996-04-09 | Ono Pharmaceutical Co., Ltd. | Polypeptide of protein p140 and DNAs encoding it |
| US5457048A (en) | 1993-12-03 | 1995-10-10 | La Jolla Cancer Research Foundation | Eph-related tyrosine kinases, nucleotide sequences and methods of use |
| CA2189028A1 (en) * | 1994-04-15 | 1995-10-26 | Gary M. Fox | Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases |
| WO2001057188A2 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU5621501A (en) | 2000-03-27 | 2001-10-08 | Bayer Aktiengesellschaft | Regulation of human ephrin-like receptor |
| AUPQ909100A0 (en) | 2000-07-28 | 2000-08-24 | Ludwig Institute For Cancer Research | A method for diagnosis and treatment |
| US20030077568A1 (en) * | 2000-09-15 | 2003-04-24 | Gish Kurt C. | Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| AU2002314433A1 (en) | 2001-07-02 | 2003-01-21 | Licentia Ltd. | Ephrin-tie receptor materials and methods |
| US20070087406A1 (en) * | 2005-05-04 | 2007-04-19 | Pei Jin | Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same |
-
2002
- 2002-04-09 GB GBGB0208089.3A patent/GB0208089D0/en not_active Ceased
-
2003
- 2003-04-09 CA CA2479835A patent/CA2479835C/en not_active Expired - Fee Related
- 2003-04-09 JP JP2003584733A patent/JP2005522229A/ja active Pending
- 2003-04-09 US US10/510,524 patent/US7655426B2/en not_active Expired - Fee Related
- 2003-04-09 WO PCT/GB2003/001593 patent/WO2003087841A2/en not_active Ceased
- 2003-04-09 EP EP03725322A patent/EP1497659A2/en not_active Withdrawn
- 2003-04-09 AU AU2003227862A patent/AU2003227862B2/en not_active Ceased
-
2009
- 2009-11-24 US US12/592,378 patent/US20110150877A1/en not_active Abandoned
- 2009-12-16 JP JP2009284833A patent/JP2010101901A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009100745A5 (enExample) | ||
| JP2008249727A5 (enExample) | ||
| JP2006518991A5 (enExample) | ||
| JP2007537197A5 (enExample) | ||
| JP2005225884A5 (enExample) | ||
| HRP20170879T1 (hr) | Genetski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena | |
| JP2005522986A5 (enExample) | ||
| JP2008517928A5 (enExample) | ||
| JP2018511319A5 (enExample) | ||
| JP2007506417A5 (enExample) | ||
| JP2009544284A5 (enExample) | ||
| JP2014527398A5 (enExample) | ||
| JP2018518151A5 (enExample) | ||
| CA2332570A1 (en) | Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine | |
| JP2008508861A5 (enExample) | ||
| JP2004505649A5 (enExample) | ||
| JP2004533825A5 (enExample) | ||
| JP2010535506A5 (enExample) | ||
| JP2004513614A5 (enExample) | ||
| JP2017523130A5 (enExample) | ||
| JP2005522229A5 (enExample) | ||
| JP2007513873A5 (enExample) | ||
| JP2005522228A5 (enExample) | ||
| EP2721072A1 (en) | Reagents and methods for bispecific antibody-based binding of target molecules | |
| RU2011130795A (ru) | Биомаркер |